After-Hours Stock Movers 01/20: (LLNW) (RGLS) Higher; (NFLX) (ISRG) (PPG) Lower (more...)

January 20, 2022 6:07 PM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

(Updated - January 20, 2022 6:07 PM EST)

After-Hours Stock Movers:

Netflix (NASDAQ: NFLX) 19.8% LOWER; reported Q4 EPS of $1.33, $0.51 better than the analyst estimate of $0.82. Revenue for the quarter came in at $7.71 billion versus the consensus estimate of $7.72 billion. Global Streaming Paid Net Additions were 8.28 million in Q4, versus 8.5 million expected. The company sees Q1 EPS of $2.86 and revenue of $7.9 billion, versus the consensus of $3.45 and $8 billion. The company sees Q1 Global Streaming Paid Net Additions of 2.5 million.

Limelight Networks (NASDAQ: LLNW) 6.4% HIGHER; reported Q4 EPS of $0.02, $0.01 better than the analyst estimate of $0.01. Revenue for the quarter came in at $62.9 million versus the consensus estimate of $61.57 million. Limelight Networks sees FY2022 EPS of ($0.06)-($0.01), versus the consensus of ($0.04). Limelight Networks sees FY2022 revenue of $240-250 million, versus the consensus of $241.2 million.

Intuitive Surgical (NASDAQ: ISRG) 5.4% LOWER; reported Q4 EPS of $1.30, $0.02 better than the analyst estimate of $1.28. Revenue for the quarter came in at $1.55 billion versus the consensus estimate of $1.52 billion.

PPG Industries (NYSE: PPG) 3.5% LOWER; reported Q4 EPS of $1.26, $0.06 better than the analyst estimate of $1.20. Revenue for the quarter came in at $4.2 billion versus the consensus estimate of $4.06 billion. PPG Industries sees Q1 2022 EPS of $1.02-$1.20, versus the consensus of $1.59.

Regulus Therapeutics Inc. (Nasdaq: RGLS) 3% HIGHER; announced that the Company has completed a pre-investigational new drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA). The purpose of the meeting was to obtain input from the FDA on pre-clinical, clinical and regulatory matters pertaining to the Company's next generation compound RGLS8429 as a potential treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The formal minutes from this meeting were received by the Company earlier this week.

CSX Corp. (NASDAQ: CSX) 2.1% LOWER; reported Q4 EPS of $0.42, in-line with the analyst estimate of $0.42. Revenue for the quarter came in at $3.43 billion versus the consensus estimate of $3.32 billion.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

After-Hours Movers, FDA